NAD+ Research Guide
Cellular metabolism research compound
NAD+ (nicotinamide adenine dinucleotide) is one of the most important coenzymes in mammalian biology, central to energy metabolism, DNA repair, and longevity-related signaling pathways. Cellular NAD+ levels decline with age, and a large body of preclinical and emerging clinical research investigates whether restoring NAD+ levels can support mitochondrial function, sirtuin activity, and metabolic health markers.
Contents
|
Coenzyme Energy metabolism |
Sirtuin Pathway substrate |
Anti-aging Research focus |
What is NAD+?
NAD+ is a dinucleotide composed of two nucleotides joined through their phosphate groups: one bears a nicotinamide base, the other an adenine base. It exists in two interconvertible forms: oxidized (NAD+) and reduced (NADH). The oxidized form is the substrate for sirtuin enzymes and PARP enzymes, both of which are central to the longevity and DNA-repair research literature.
Cellular NAD+ levels decline measurably with age in mammalian tissues. Multiple research groups have demonstrated approximately 50% reduction in NAD+ between young adulthood and advanced age in human and animal tissue samples. This decline is hypothesized to contribute to the metabolic and regenerative deficits associated with aging.
Aeternum Labs supplies NAD+ as a lyophilized powder for in vitro research applications. Each batch is verified to 99%+ purity by HPLC, with full Certificate of Analysis published in the public COA library.
Mechanism of action
In energy metabolism, NAD+ is the primary electron acceptor in glycolysis and the citric acid cycle. The reduction of NAD+ to NADH captures the energy released during catabolism of carbohydrates, fats, and proteins. NADH then donates these electrons to the mitochondrial electron transport chain to drive ATP synthesis.
Beyond energy metabolism, NAD+ is the consumed substrate for two critical enzyme families: sirtuins (which remove acetyl groups from histone and non-histone proteins, regulating gene expression and metabolic state) and PARPs (which mark sites of DNA damage for repair). Both consume NAD+ in their catalytic cycle, linking cellular NAD+ availability directly to genomic maintenance and metabolic adaptation.
The longevity research literature on NAD+ is built on the observation that increasing NAD+ availability in cells and tissues extends lifespan and healthspan in multiple model organisms. The mechanism is hypothesized to involve enhanced sirtuin activity, improved mitochondrial function, and more efficient DNA repair throughout the aged cellular environment.
Research history
NAD+ was first identified in 1906 by Arthur Harden and William John Young in studies of yeast fermentation. Its role as the universal hydrogen carrier in cellular metabolism was characterized through the 1930s by Otto Warburg and others, work that contributed to multiple Nobel Prizes.
Modern NAD+ research as it relates to aging and metabolic health emerged through the late 1990s and 2000s, driven by the discovery of sirtuin enzymes by Lenny Guarente and the demonstration that sirtuin activity is rate-limited by NAD+ availability. Subsequent work by David Sinclair, Shin-ichiro Imai, and others established the link between declining NAD+ levels and age-related metabolic decline.
The most recent research wave has focused on practical strategies for restoring NAD+ in aged tissues. NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) and direct NAD+ supplementation are both active areas of investigation, with multiple human clinical trials now in progress.
Half-life and pharmacokinetics
Direct NAD+ administration in research uses intravenous, intramuscular, or subcutaneous routes. Oral bioavailability of NAD+ itself is limited because the molecule is degraded in the gut before reaching systemic circulation; precursors like nicotinamide riboside and NMN are commonly used as orally-bioavailable alternatives.
Tissue distribution of administered NAD+ varies. Liver and muscle tissue show measurable elevation in published animal studies, while brain tissue elevation requires either direct administration or precursor strategies that cross the blood-brain barrier and are converted to NAD+ in situ.
Typical research doses
Research dose ranges in published animal NAD+ administration studies span approximately 1 mg/kg to 100 mg/kg per administration, depending on the route and the specific endpoint studied. Mitochondrial function and longevity studies tend to use chronic low-dose administration, while acute metabolic challenge studies use higher single doses.
For human research, the dose ranges in published clinical studies of intravenous NAD+ infusion span 250 mg to 1500 mg per session, with frequencies ranging from daily during initial loading periods to weekly or biweekly maintenance. Individual research protocols vary widely in dose and frequency depending on the endpoint of interest.
Compliance reminder
All dose ranges discussed are reported from peer-reviewed in vitro and animal research. They are not human-use dose recommendations.
Reconstitution protocol
Lyophilized peptides require reconstitution with a sterile solvent before any in vitro work. The standard solvent across virtually all research-peptide protocols is bacteriostatic water (sterile water with 0.9% benzyl alcohol), which prevents microbial growth across the typical four-week working window once a vial is opened.
Add the solvent slowly down the inside wall of the vial rather than directly onto the lyophilized cake. Swirl gently until the powder dissolves fully. Do not shake — agitation can denature peptide bonds and reduce assay potency. A clear, particle-free solution should result within thirty to sixty seconds.
Volume calculations are straightforward. For a 10 mg vial reconstituted with 2 mL of bacteriostatic water, each 0.1 mL of the resulting solution contains 0.5 mg of peptide. Researchers planning multi-week protocols should compute their volumes ahead of time and document the lot number against each preparation.
Storage and stability
Sealed lyophilized vials are stable at 0°F (−18°C) for up to twenty-four months in most research literature. Vials should be kept dry, light-protected, and away from temperature fluctuations. Avoid storing peptides in the freezer door, where each open-close cycle introduces thermal stress.
Once reconstituted, store the working solution at 36–46°F (2–8°C). Most lyophilized peptides remain stable in solution for twenty-eight days under refrigeration with bacteriostatic water as the diluent. For protocols longer than four weeks, reconstitute fresh batches as needed rather than extending a single working vial.
Repeated freeze-thaw cycles reduce peptide integrity. If long-term storage of a reconstituted sample is required, aliquot the solution into single-use volumes before freezing so each thaw uses a fresh aliquot.
NAD+ is particularly sensitive to oxidation, light, and freeze-thaw cycles. Storage in amber vials or in dark-protected containers is recommended. Working solutions should be prepared fresh from frozen lyophilized stock when possible rather than relying on long-term refrigerated solutions.
Common stack pairings
NAD+ + GHK-Cu (longevity and tissue research)
GHK-Cu modulates gene expression in patterns associated with younger tissue states. Combined with NAD+ restoration, this stack is researched for cellular and tissue rejuvenation endpoints across multiple model systems.
NAD+ + Tesamorelin (metabolic and body composition research)
Tesamorelin’s GHRH-mediated effects on mitochondrial biogenesis pair with NAD+’s role in mitochondrial function. The combination is researched for metabolic and body composition endpoints in aging-related research models.
How it compares
Compared to nicotinamide riboside (NR): NR is an orally-bioavailable NAD+ precursor that the cell converts to NAD+ in situ. Direct NAD+ administration bypasses the conversion step but requires injection or infusion routes. Different research contexts favor different approaches.
Compared to nicotinamide mononucleotide (NMN): NMN is also an oral NAD+ precursor with similar biological behavior to NR. Both NMN and NR are commonly compared in head-to-head research designs to assess differential efficiency of NAD+ pool elevation.
From the Aeternum library
NAD+ (lyophilized)
- 99%+ purity verified by HPLC
- LAL endotoxin screening
- Full Certificate of Analysis published
- Light-protected packaging
- Lyophilized powder
Frequently asked questions
What is the difference between NAD+ and NADH?
NAD+ is the oxidized form, NADH is the reduced form. The two interconvert as cellular metabolism captures and releases energy. NAD+ specifically is the substrate for sirtuin and PARP enzymes, which is why the oxidized form is the focus of most longevity research.
Why does cellular NAD+ decline with age?
Multiple mechanisms contribute, including increased PARP activity in response to accumulating DNA damage (which consumes NAD+), declining synthesis efficiency, and increased CD38 enzyme expression which degrades NAD+ at faster rates in aged tissue. The net effect is a measurable approximate 50% reduction in cellular NAD+ between young adulthood and advanced age.
How does NAD+ administration compare to using NMN or NR precursors?
Direct NAD+ administration delivers the active molecule but requires injection or infusion. NMN and NR are orally-bioavailable precursors that the cell converts to NAD+ in situ. Different research applications favor different approaches depending on the target tissue, the desired pharmacokinetic profile, and the route of administration the protocol allows.
What are the typical research dose ranges?
Animal research uses 1–100 mg/kg per administration depending on route and endpoint. Human clinical research using intravenous NAD+ infusion typically uses 250–1500 mg per session with frequencies from daily loading to weekly maintenance.
How is NAD+ stored?
NAD+ is sensitive to oxidation, light, and freeze-thaw cycles. Sealed lyophilized vials are stored at 0°F (−18°C) in light-protected packaging for long-term stability. Working solutions should ideally be prepared fresh from frozen stock rather than stored in solution for extended periods.
References
- Imai S, Guarente L (2014). NAD+ and sirtuins in aging and disease. View source
- Yoshino J, Baur JA, Imai S (2018). NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. View source
- Verdin E (2015). NAD+ in aging, metabolism, and neurodegeneration. View source
- Mills KF, Yoshida S, Stein LR, et al. (2016). Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. View source
Reviewed by
The Aeternum Labs Research Team
Compounds, COAs, and protocol design
The Aeternum Labs research team verifies every batch in our library against published purity and identity standards. Articles in our research blog summarize publicly available scientific literature and are reviewed for accuracy by team members trained in peptide biochemistry and laboratory protocol design.
Related research
Category
Best peptides for longevity research →
Pair with
GHK-Cu research guide →
Pair with
MOTS-c research guide →
Pair with
Glutathione research guide →
Research Disclaimer. All compounds discussed in this article are sold by Aeternum Labs for in vitro laboratory research purposes only. They are not intended for human or animal consumption, diagnosis, treatment, or prevention of any disease or condition. Information presented is summarized from publicly available scientific literature and should not be construed as medical advice.